U013 Practical Updates in Adult-onset Mastocytosis, MCAS, and HAT for the Dermatologist
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Systemic mastocytosis is characterized by the proliferation and accumulation of mast cells in a variety of organs resulting in dysfunction and morbidity. Cutaneous manifestations provide an important clue to diagnosis, thus dermatologists play a vital role in identification. As systemic involvement is present in the vast majority of adults with mastocytosis in the skin, an improved understanding of the implications of cutaneous disease is necessary. Additionally, patients are increasingly presenting with cutaneous symptoms related to diagnoses such as mast cell activation syndrome (MCAS) and hereditary alpha tryptasemia (HAT). This session will provide an up-to-date perspective for a dermatology audience.
LEARNING OBJECTIVES
Identify the clinical manifestations of mastocytosis presenting in the skin and implications on prognosis with a focus on the adult population and recent updates in terminology.
Outline a straightforward diagnostic algorithm for assessing patients with mastocytosis in the skin and briefly review novel therapeutics.
Improve familiarity with mast cell activation syndrome and hereditary alpha tryptasemia and the implications of these conditions in the skin.
SCHEDULE
12:30 PM
Case Presentation
Lauren Michelle Madigan, MD, FAAD
12:40 PM
Cutaneous manifestations of mastocytosis
Karin Hartmann, MD
1:00 PM
MCAS & HAT for the Dermatologist
Mariana Castells
1:15 PM
Final Case Presentation/Q&A
SPEAKERS
Mariana Castells
Karin Hartmann, MD
Lauren Michelle Madigan, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Mariana Castells
Blueprint Medicines – Investigator(Grants/Research Funding); Cogent Biosciences – Investigator(Grants/Research Funding); Daiichi Sankyo – Consultant (1099 relationship)(Honoraria); NIH – Data Safety Monitoring Board(Honoraria); Telios Pharmaceuticals – Investigator(Grants/Research Funding);
Karin Hartmann, MD
No financial relationships exist with ineligible companies.
Lauren Michelle Madigan, MD, FAAD
Blueprint Medicines – Advisory Board(Honoraria);